

DAFTAR PUSTAKA

1. Wang H, Men P, Xiao Y, Gao P, Lv M, Yuan Q, et al. Hepatitis B infection in the general population of China: A systematic review and meta-analysis. *BMC Infect Dis.* 2019 Sep 18;19(1):1-10.
2. Sali S, Merza MA, Saadat S, Mustafa NH, Queiky F, Yadegarynia D. Seroclearance of Hbsag in Chronic Hepatitis B virus patients on lamivudine therapy: A 10 Year Experience. *Glob J Health Sci.* 2015;7(6):101-107.
3. Yano Y, Utsumi T, Lusida MI, Hayashi Y. Hepatitis B virus infection in Indonesia. *World J Gastroenterol.* 2015;21(38):10714-10720.
4. Mauss S, Berg T, Rockstroh J, Sarrazin C WH. Hepatology, Tenth Edition. 2020:1-61.
5. Siburian MD, Utama A, Dhenni R, Arnelis, Fanany I, Intan MDB, et al. High prevalence of hepatitis B virus genotype C/C1 in the Minangkabau ethnic group in Indonesia. *Viol J.* 2013;10(1):1.
6. Andriani Y, Sari CP, Setyaningrum N. Evaluasi pengobatan pada pasien Hepatitis B rawat jalan di Rumah Sakit Yogyakarta. 2020;(Nov):65-75.
7. Riskesdas K. Hasil utama riset kesehata dasar (RISKESDAS). *J Phys A Math Theor.* 2018;44(8):1-200.
8. Dinkes Provinsi Sumbar. Profil dinas kesehatan Sumatera Barat tahun 2017. *Germas.* 2017:145. www.dinkes.sumbarprov.go.id.
9. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic Hepatitis B virus infection: A systematic review of data published between 1965 and 2013. *Lancet.* 2015;386(10003):1546-1555.
10. Kayode MJ, Naghavi M, Abajobir A, Abbafati C, Abbas K, Abera S, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global burden of disease study 2016. *Lancet.* 2017;390(10100):1151-1210.
11. Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of Hepatitis B virus infection and impact of vaccination on disease. *Clin Liver Dis.* 2016 Nov;20(4):607-628.
12. States U. Viral Hepatitis surveillance. 2014. <https://www.cdc.gov/hepatitis/statistics/2014surveillance/index.htm>
13. Wilkins T, Zimmerman D, Schade RR. Hepatitis B: Diagnosis and

treatment. *Am Fam Physician*. 2019;81(8):965-972.

14. Fadrian F. Terapi antiviral pada sirosis hati dekompensata terkait infeksi virus Hepatitis B. *Maj Kedokt Andalas*. 2016;39(1):35.
15. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of Hepatitis B: A 2015 update. *Hepatol Int*. 2016 Jan;10(1):1-98.
16. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, et al. Aktualisierung der S 3-leitlinie zur prophylaxe, diagnostik und therapie der Hepatitis-B-virusinfektion. *Z Gastroenterol*. 2011;49(07):871-930.
17. Liaw Y-F, Sung JJY, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic Hepatitis B and advanced liver disease. *N Engl J Med*. 2004;351(15):1521-1531.
18. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of Hepatitis B: Summary of a clinical research workshop. *Hepatology*. 2007;45(4):1056-1075.
19. Cornberg M, Lok ASF, Terrault NA, Zoulim F. Guidance for design and endpoints of clinical trials in chronic Hepatitis B—Report from the 2019 EASL-AASLD HBV treatment endpoints conference. *Hepatology*. 2020;71(3):1070-1092.
20. Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. *Gut*. 2013;62(5):760-765.
21. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature. *Hepatology*. 2003;37(6):1309-1319.
22. Kim JH, Sinn DH. Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change? *Clin Mol Hepatol*. 2020;26(3):315-317.
23. Poordad F, Reddy KR, Martin P. Rapid virologic response: A new milestone in the management of chronic Hepatitis C. *Clin Infect Dis*. 2008;46(1):78-84.
24. Wong GLH, Wong VWS, Chan HY, Tse PCH, Wong J, Chim AML, et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic Hepatitis B patients at 3 years. *Aliment Pharmacol Ther*. 2012;35(11):1326-1335.

25. Idilman R. The summarized of EASL 2017 Clinical practice guidelines on the management of Hepatitis B virus infection. *Turkish J Gastroenterol.* 2017;28(5):412-416.
26. Zoutendijk R, Reijnders JGP, Brown A, Zoulim F, Mutimer D, Deterding K, et al. Entecavir treatment for chronic Hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response. *Hepatology.* 2011;54(2):443-451.
27. Nassal M. HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic Hepatitis B. *Gut.* 2015;64(12):1972-1984.
28. Bisht BS. International journal of current research in chemistry and pharmaceutical sciences evaluation of antianxiety activity of zonisamide based on the serendipitous action in Swiss albino mice. *Int J Curr Res Chem Pharm Sci.* 2019;6(4):27-32.
29. Karnsakul W, Schwarz KB. Hepatitis B and C. *Pediatr Clin North Am.* 2017;64(3):641-658.
30. Eni AO, Soluade MG, Oshamika OO, Efekemo OP, Igwe TT, Onile-Ere OA. Knowledge and awareness of Hepatitis B virus infection in Nigeria. *Ann Glob Heal.* 2019;85(1):1-6.
31. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. *World J Hepatol.* 2012;4(3):74-80.
32. Dandri M, Petersen J. Mechanism of Hepatitis B virus persistence in hepatocytes and its carcinogenic potential. *Clin Infect Dis.* 2016;62(4):281-288.
33. World Health Organization. (2017). Global Hepatitis report 2017: executive summary. World Health Organization. <https://apps.who.int/iris/handle/10665/255017>.
34. Brown RS, McMahon BJ, Lok ASF, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral therapy in chronic Hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. *Hepatology.* 2016;63(1):319-333.
35. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. *Blood.* 2019;133(17):1854-1864.
36. Amini-Bavil-Olyae S, Maes P, Van Ranst M, Pourkarim MR. Providing strong evidence of nosocomial outbreak of Hepatitis B virus infection. *J Hosp Infect.* 2012;80(3):269-270.

37. Karayiannis P. Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread. *Hepatol Int.* 2017;11(6):500-508.
38. Doto JB. Hepatitis B : Pathophysiology, protection, and patients. *Rnj.* 2013. Copyright © 2013 by RN.com.
39. Busca A, Kumar A. Innate immune responses in Hepatitis B virus (HBV) infection. *Virol J.* 2014;11(1):1-8.
40. Chisari F V., Isogawa M, Wieland SF. Pathogenèse de i'infection par le virus de l'Hépatite B. *Pathol Biol.* 2010;58(4):258-266.
41. Lumley SF, McNaughton AL, Klenerman P, Lythgoe KA, Matthews PC. Hepatitis B virus adaptation to the CD8+ T cell response: Consequences for host and pathogen. *Front Immunol.* 2018;9(JUL):1-14.
42. Tsai KN, Kuo CF, Ou JHJ. Mechanisms of Hepatitis B virus persistence. *Trends Microbiol.* 2018;26(1):33-42.
43. Burns GS, Thompson AJ. Viral hepatitis B: Clinical and epidemiological characteristics. *Cold Spring Harb Perspect Med.* 2014 Oct 30;4(12):1-14.
44. Song JE, Kim DY. Diagnosis of Hepatitis B. *Ann Transl Med.* 2016 Sep;4(18):338.
45. Zhong Y, Hu S, Xu C, Zhao Y, Xu D, Zhao J, et al. A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR. *BMC Infect Dis.* 2014 Dec 3;14(1):608.
46. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic Hepatitis B virus infection. *J Hepatol.* 2012;57(1):167-185.
47. Jalaluddin S. Transmisi Vertikal Virus Hepatitis B. *Stud Pendidik Dr Fak Ilmu Kedokt dan Kesehatan, Progr.* 2018:1-191.
48. Flisiak R, Halota W, Jaroszewicz J, Juszczak J, Malkowski P, Pawlowska M, et al. Recommendations for the treatment of Hepatitis B in 2017. *Clin Exp Hepatol.* 2017;3(2):35-46.
49. Perhimpunan Peneliti Hati Indonesia (PPHI). Konsensus nasional penatalaksanaan Hepatitis B di Indonesia. Jakarta:PPHI;2017
50. Geller SA. Hepatitis B and Hepatitis C. *Clin Liver Dis.* 2016;6(2):317-334.
51. Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic Hepatitis B. *Cold Spring Harb Perspect Med.* 2015;5(4):1-21.

52. World Health Organisation. Guideline for the prevention, care and treatment of persons with chronic Hepatitis B infection. 2015;(Apr):124.
53. Gani RA, Hasan I, Djumhana A, Setiawan PB. *Konsensus nasional pelaksanaan Hepatitis B.*; 2012.
54. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic Hepatitis B: A 2012 update. *Hepatol Int.*2012 Jun;6(3):31-61.
55. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with Hepatitis B virus infection. *Hepatology.* 2013;58(1):98-107.
56. Tong MJ, Pan CQ, Han SHB, Lu DSK, Raman S, Hu KQ, et al. An expert consensus for the management of chronic Hepatitis B in Asian Americans. *Aliment Pharmacol Ther.* 2018;47(8):1181-1200.
57. Marcellin P, Chang TT, Lim SGL, Sievert W, Tong M, Arterburn S, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of Hepatitis B e antigen-positive chronic Hepatitis B. *Hepatology.* 2008;48(3):750-758.
58. Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic Hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Gastroenterol Hepatol.* 2016;1(3):196-206.
59. Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic Hepatitis B virus infection. *Liver Int.* 2019;39(10):1868-1875.
60. Ait-Goughoulte M, Lucifora J, Zoulim F, Durantel D. Innate antiviral immune responses to hepatitis B virus. *Viruses.* 2010;2(7):1394-1410.
61. Ishikawa T. Immunoregulation of Hepatitis b virus infection: Rationale and clinical application. *Nagoya J Med Sci.* 2012;74(3-4):217-232.
62. Neumann AU, Phillips S, Levine I, Ijaz S, Dahari H, Eren R, et al. Novel mechanism of antibodies to Hepatitis B virus in blocking viral particle release from cells. *Hepatology.* 2010;52(3):875-885.
63. Kumar R, Teo EK, How HC, Wong TY, Ang TL. A practical clinical approach to liver fibrosis. *Singapore Med J.* 2018;59(12):628-633.
64. Aydin MM, Akcali KC. Liver fibrosis. *Turkish J Gastroenterol.*

2018;29(1):14-21.

65. Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). *BMC Gastroenterol.* 2010;10:40.
66. Gani RA, Hasan I, Lesmana RA. Naskah Lengkap The 12th liver update and the annual scientific meeting of INA ASL/PPHI 2019. 2017:43-50.
67. Shi YX, Huang CJ, Yang ZG. Impact of Hepatitis B virus infection on hepatic metabolic signaling pathway. *World J Gastroenterol.* 2016;22(36):8161-8167.
68. Na TY, Ka NL, Rhee H, Kyeong D, Kim MH, Seong JK, et al. Interaction of Hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma. *Oncogene.* 2016;35(41):5435-5445.
69. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. *Gastroenterology.* 2014;146(4):1070-1083.
70. Papatheodoridis G V., Chan HLY, Hansen BE, Janssen HLA, Lampertico P. Risk of hepatocellular carcinoma in chronic Hepatitis B: Assessment and modification with current antiviral therapy. *J Hepatol.* 2015;62(4):956-967.
71. Wikan Trisnaningtyas R. Evaluasi terapi pada pasien Hepatitis B di RSUP Dr. Sardjito Yogyakarta. *J Ilm Farm.* 2017;13(1):27-33.
72. Jo YJ, Kim KA, Lee JS, Kim NH, Bae WK, Song TJ, et al. Long-term virological outcome in chronic Hepatitis B patients with a partial virological response to entecavir. *Korean J Intern Med.* 2015;30(2):170-176.
73. Tang CM, Yau TO, Yu J. Management of chronic Hepatitis B infection: Current treatment guidelines, challenges, and new developments. *World J Gastroenterol.* 2014;20(20):6262-6278.
74. Ruggieri A, Gagliardi MC, Anticoli S. Sex-dependent outcome of Hepatitis B and C viruses infections: Synergy of sex hormones and immune responses? *Front Immunol.* 2018;9:1-7.
75. Budi SRM, Lubis R, Rasmaliah. Karakteristik penderita Hepatitis B rawat inap di RSUD Dr. Pirngadi Medan tahun 2015-2016. *Depart Epid FKM USU.* 2014;17(1):89-95.

76. Pradono J, Sulistyowati N. Hubungan antara tingkat pendidikan, pengetahuan tentang kesehatan lingkungan, perilaku hidup sehat dengan status kesehatan (Studi korelasi pada penduduk umur 10-24 tahun di Jakarta Pusat). *Bul Penelit Sist Kesehat.* 2014;17(1):89-95.
77. Siakavellas S, Goulis J, Manolakopoulos S, Triantos C, Gatselis N, Tsentemidou E, et al. Monitoring and comorbidities in patients with chronic Hepatitis B currently treated with nucleos(t)ide analogs. *Ann Gastroenterol.* 2021;34(1):73-79.
78. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American association for the study of liver diseases. AASLD guidelines for treatment of chronic Hepatitis B. *Hepatology.* 2016;63(1):261-83.
79. Buti M, Roade L, Riveiro-Barciela M, Esteban R. Optimal management of chronic Hepatitis B patients receiving nucleos(t)ide analogues. *Liver Int.* 2020;40(1):15-21.
80. Agarwal K, Fung S, Seto WK, Lim YS, Gane E, Janssen HL, et al. A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic Hepatitis B (CHB): efficacy and safety results at week 96. *J Hepatol.* 2017;66(1):478.
81. Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, et al. Comparison between chronic Hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. *Sci Rep.* 2019;9(1):4-11.
82. Ismail S, Hafez HA, Darweesh SK, Kamal KH, Esmat G. Virologic response and breakthrough in chronic Hepatitis B Egyptian patients receiving lamivudine therapy. *Ann Gastroenterol.* 2014;27(4):380-386.
83. Shao YY, Chen PJ, Lin ZZ, Huang CC, Ding YH, Lee YH, et al. Impact of baseline Hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma. *Anticancer Res.* 2011;31(11):4007-4011.
84. Ghany MG, Doo EC. Antiviral resistance and Hepatitis B therapy. *Hepatology.* 2009;49(5):1-20.
85. Si Ahmed SN, Zoulim F. Pathobiology of HBV mutants and clinical impact for treatment monitoring. *Expert Rev Anti Infect Ther.* 2009;7(3):309-320.
86. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. *Gastroenterology.* 2009;137(5):1593-1608.